Mackenzie Financial Corp Purchases Shares of 453,615 TransMedics Group, Inc. (NASDAQ:TMDX)

Mackenzie Financial Corp acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 453,615 shares of the company's stock, valued at approximately $35,804,000. Mackenzie Financial Corp owned about 1.39% of TransMedics Group at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Comerica Bank purchased a new position in shares of TransMedics Group during the third quarter valued at approximately $34,000. Global Retirement Partners LLC purchased a new position in shares of TransMedics Group during the third quarter valued at approximately $38,000. Cutler Group LLC CA lifted its holdings in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company's stock valued at $38,000 after purchasing an additional 600 shares during the last quarter. Ancora Advisors LLC purchased a new position in shares of TransMedics Group during the first quarter valued at approximately $38,000. Finally, First Horizon Advisors Inc. increased its position in shares of TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock valued at $41,000 after acquiring an additional 169 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on TMDX. Oppenheimer lifted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a report on Tuesday, February 27th. Piper Sandler assumed coverage on TransMedics Group in a research note on Thursday, March 28th. They set an "overweight" rating and a $95.00 price objective on the stock. Finally, Morgan Stanley boosted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $102.00.

TransMedics Group Trading Down 0.7 %

Shares of TMDX stock traded down $0.62 during mid-day trading on Thursday, hitting $87.24. 692,313 shares of the stock were exchanged, compared to its average volume of 688,977. The firm has a fifty day moving average of $83.01 and a 200 day moving average of $72.88. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group's quarterly revenue was up 158.6% compared to the same quarter last year. During the same period last year, the company posted ($0.21) EPS. Analysts predict that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,330 shares of the firm's stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the transaction, the insider now directly owns 14,375 shares of the company's stock, valued at approximately $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of the firm's stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the transaction, the insider now directly owns 14,375 shares of the company's stock, valued at approximately $1,295,043.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the transaction, the insider now directly owns 14,375 shares in the company, valued at $1,295,043.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 119,408 shares of company stock valued at $10,182,881. 6.70% of the stock is owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.